Please login to the form below

Not currently logged in
Email:
Password:

Lucid Group names Neil Flash chief commercial officer

Flash joins the team from dna Communications

Neil Flash

Lucid Group has appointed Neil Flash as its new chief commercial officer, who joins from dna Communications.

In his previous role at dna, Flash served as EMEA managing director for six years. As managing director, he was responsible for the company’s brand proposition across the EMEA region, as well as the expansion of its client partner portfolio.

Prior to joining dna, he spent over five years at each of Huntsworth Health, Virgo and Cohn & Wolfe.

Flash has spent much of his career working for a number of major pharmaceutical and life sciences companies.

He has represented brands across each stage of the lifecycle, helping client partners to navigate the evolving healthcare sector across the UK, EMEA, Asia Pacific and global locations.

In addition to his career experience, Flash has a scientific background gained from a degree in BioMedical Science from Portsmouth University.

He has also been part of numerous award-winning teams, including those which have won agency award from Communiqué, Holmes Report and PRWeek. In addition, he has worked on award-winning campaigns recognised by Communiqué, PM Society and PR Week, and is a regular Communiqué judge.

“Neil is an exceptional communications professional and a talent we have admired for some time. His balance of commercial strategy, business and people focus make him a perfect fit for Lucid as he leads a core part of our business,” said Dennis O’Brien, Lucid Group CEO.

Article by
Lucy Parsons

22nd January 2020

From: Marketing

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics